Conor Chandler
Overview
Explore the profile of Conor Chandler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
34
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garcia C, Abrahami D, Polli A, Chu H, Chandler C, Tan M, et al.
Clin Lung Cancer
. 2024 Sep;
25(7):634-642.
PMID: 39232917
Introduction: The comparative efficacy and safety of lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), versus second-generation ALK TKIs as a first-line treatment for ALK+ advanced/metastatic nonsmall...
2.
Kim T, Girard N, Leighl N, Sabari J, Rahhali N, Schioppa C, et al.
Future Oncol
. 2023 Oct;
20(8):447-458.
PMID: 37882460
We assessed relative efficacy and safety of amivantamab versus mobocertinib in patients with non-small-cell lung cancer with exon 20 insertion (exon20ins) mutations who progressed on prior platinum-based chemotherapy. This matching-adjusted...
3.
Chandler C, Burnett H, Schaible K, Senthil V, Kato M, Miura Y, et al.
J Med Econ
. 2023 Jul;
26(1):1009-1018.
PMID: 37505931
Aims: The treatment landscape of renal cell carcinoma has changed with the introduction of targeted therapies. While the clinical benefit of cabozantinib is well-established for Japanese patients who have received...
4.
McGarry L, Bhaiwala Z, Lopez A, Chandler C, Pelligra C, Rubin J, et al.
PLoS One
. 2023 Apr;
18(4):e0283479.
PMID: 37043485
Objectives: Cystic fibrosis (CF) is a rare genetic disease characterized by life-shortening lung function decline. Ivacaftor, a CF transmembrane conductance regulator modulator (CFTRm), was approved in 2012 for people with...
5.
Chandler C, Folse H, Gal P, Chavan A, Proskorovsky I, Franco-Villalobos C, et al.
J Mark Access Health Policy
. 2021 Jun;
9(1):1922163.
PMID: 34122780
: Simulation modeling facilitates the estimation of long-term health and economic outcomes to inform healthcare decision-making. : To develop a framework to simulate progression of Parkinson's disease (PD), capturing motor...
6.
Rubin J, OCallaghan L, Pelligra C, Konstan M, Ward A, Ishak J, et al.
Ther Adv Respir Dis
. 2019 Feb;
13:1753466618820186.
PMID: 30803355
Background: Lumacaftor/ivacaftor combination therapy is efficacious and generally safe for patients with cystic fibrosis (CF) homozygous for the F508del-CF transmembrane conductance regulator (CFTR) mutation. However, long-term survival benefits of lumacaftor/ivacaftor...
7.
Pelligra C, Parikh K, Guo S, Chandler C, Mouro J, Abouzaid S, et al.
Clin Ther
. 2017 Oct;
39(10):1986-2005.e5.
PMID: 28967482
Purpose: Pomalidomide plus low-dose dexamethasone (POM-d), daratumumab monotherapy (DARA), and carfilzomib monotherapy (CAR) have been approved for use in the treatment of patients with heavily pretreated relapsed-refractory multiple myeloma (RRMM)...